Home
Career Stage
Medical Students Residents Attendings CPT Codes Resources Blog Support

J0584 Injection, burosumab-twza 1m

J Codes (Drugs)

Also known as: burosumab-twza, Crysvita

Burosumab-twza injection, 1 milligram, a monoclonal antibody against fibroblast growth factor 23 (FGF23) for X-linked hypophosphatemia treatment.

In Plain Language

genetic bone disease treatment; phosphate regulation medication

Clinical Context

First-in-class FGF23 antagonist indicated for X-linked hypophosphatemia, a hereditary disorder causing severe hypophosphatemia and rickets. Corrects phosphate reabsorption by inhibiting FGF23 signaling.

RVU Information

CPT J0584 does not have a physician work RVU assigned by CMS. This is typical for supply, drug, and equipment codes — reimbursement is based on Average Sales Price (ASP), fee schedules, or payer contracts rather than the RVU system.

Billing & Documentation

J-codes represent drugs administered by a healthcare provider (not self-administered). Documentation must include the drug name, dosage, route of administration, and medical necessity. Most payers require the National Drug Code (NDC) on the claim. Bill the appropriate administration code (96365-96379) in addition to the drug code.

Specialties

endocrinologypediatricsgenetic medicine

Frequently Asked Questions

What is CPT code J0584?

CPT J0584 (Injection, burosumab-twza 1m) is a J Codes (Drugs) code. Burosumab-twza injection, 1 milligram, a monoclonal antibody against fibroblast growth factor 23 (FGF23) for X-linked hypophosphatemia treatment.

How is J0584 administered?

CPT J0584 is administered by a healthcare provider, typically via injection or infusion. First-in-class FGF23 antagonist indicated for X-linked hypophosphatemia, a hereditary disorder causing severe hypophosphatemia and rickets. Corrects phosphate reabsorption by inhibiting FGF23 signaling. It is used by endocrinology, pediatrics, genetic medicine.

When is CPT J0584 used?

First-in-class FGF23 antagonist indicated for X-linked hypophosphatemia, a hereditary disorder causing severe hypophosphatemia and rickets. Corrects phosphate reabsorption by inhibiting FGF23 signaling.

Track This Code in RVU Edge

Log procedures, calculate wRVUs, and benchmark against MGMA data — all in one app.

CPT® is a registered trademark of the American Medical Association. Data sourced from CMS Physician Fee Schedule RVU26A. Descriptions, synonyms, and clinical context are original content by RVU Edge.